Refine by
Aptevo Cancer A Case Study Equipment & Supplies
1 equipment items found
Manufactured by:Aptevo Therapeutics based inSeattle, WASHINGTON (USA)
APVO436 is an optimized ADAPTIR bispecific antibody candidate designed to redirect T-cell cytotoxicity through the dual targeting of CD3, a T-cell co-receptor that promotes cytotoxicity, and CD123, a cell surface receptor highly expressed in several hematological malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, hairy cell leukemia, myelodysplastic syndrome, and ...